CN111107867B - 包含护脑素的防止脱发或毛发生长促进用组合物 - Google Patents
包含护脑素的防止脱发或毛发生长促进用组合物 Download PDFInfo
- Publication number
- CN111107867B CN111107867B CN201880061002.8A CN201880061002A CN111107867B CN 111107867 B CN111107867 B CN 111107867B CN 201880061002 A CN201880061002 A CN 201880061002A CN 111107867 B CN111107867 B CN 111107867B
- Authority
- CN
- China
- Prior art keywords
- hair
- humanin
- composition
- preventing
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000003779 hair growth Effects 0.000 title claims abstract description 32
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 201000004384 Alopecia Diseases 0.000 title claims description 24
- 231100000360 alopecia Toxicity 0.000 title claims description 11
- 210000004556 brain Anatomy 0.000 title abstract description 16
- 239000003223 protective agent Substances 0.000 title description 4
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 claims abstract description 49
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 claims abstract description 48
- 102000011854 humanin Human genes 0.000 claims abstract description 48
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 14
- 230000001256 tonic effect Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 210000004209 hair Anatomy 0.000 claims description 80
- 239000006071 cream Substances 0.000 claims description 18
- -1 hair mask Substances 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 210000003780 hair follicle Anatomy 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 230000003698 anagen phase Effects 0.000 description 11
- 230000003676 hair loss Effects 0.000 description 11
- 208000024963 hair loss Diseases 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 8
- 229960003632 minoxidil Drugs 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000003797 telogen phase Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000003778 catagen phase Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001012 protector Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000003135 vibrissae Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- DHVJQUFZGZOFFY-UHFFFAOYSA-N (6-amino-2-imino-4-piperidin-1-ylpyrimidin-1-yl) hydrogen sulfate Chemical compound N=C1N(OS(O)(=O)=O)C(N)=CC(N2CCCCC2)=N1 DHVJQUFZGZOFFY-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000841 minoxidil sulfate Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XGSXUSCKTLWSLU-UHFFFAOYSA-N 3-[dimethyl(trimethylsilyloxy)silyl]propan-1-ol Chemical compound C[Si](C)(C)O[Si](C)(C)CCCO XGSXUSCKTLWSLU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GSSWFBLVISCYBP-UHFFFAOYSA-N 3-chloropropyl-dimethyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)CCCCl GSSWFBLVISCYBP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001655736 Catalpa bignonioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical group CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AMNQQNTZDFYVGH-UHFFFAOYSA-N dimethyl-phenyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)C1=CC=CC=C1 AMNQQNTZDFYVGH-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000003693 proliferative and anti-apoptotic effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Marine Sciences & Fisheries (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及包含护脑素的防止脱发或毛发生长促进用药学组合物。包含护脑素的组合物被认定为具有抑制及预防脱发且促进毛发生长的功效，因此可在药学、化妆品及美容等领域中以多种方式应用。
Description
技术领域
本发明涉及包含护脑素(Humanin)的防止脱发或毛发生长促进用组合物。
背景技术
护脑素是由24个氨基酸形成的多肽(poly-peptide)，其在幸存于阿尔茨海默氏病(Alzheimer's disease)患者的大脑中的神经元中发现。由于护脑素对细胞凋亡具有保护作用，因而可使脑神经元存活而不被破坏(Hashimoto Y.，et al，.2001a)。原护脑素(HN)的第14个氨基酸碱基由丝氨酸(serine)被取代为甘氨酸(glycine)的护脑素(HNG)其强度比原护脑素(HN)的活性高1000倍，因而具有很强的效果(Hashimoto et al.，2001a，b，c)。据报道，当用这种护脑素(HNG)处理细胞时，有57种蛋白质被磷酸化。被护脑素(HNG)磷酸化的57种蛋白质根据其功能分为激酶(kinase)、转录调节剂(transcription regulator)、平移调节剂(translational regulator)、跨膜受体(transmembrane receptor)、转运蛋白(transporter)等(Su-Jeong K.，et al.，The mitochondrial-derived peptide humaninactivates the ERK1/2，AKT，and STAT3 signaling pathways and has age-dependentsignaling differences in the hippocampus.oncotarget.7.46899-46912.(2016))。
人体的毛发在“毛囊”中形成，其数量约为10万～15万根。毛囊中具有毛乳头，在此部位中分布有小血管，用于供给毛发生长中所需的营养成分，在毛乳头上的旁边具有皮脂腺，用于供给使毛发润泽的油脂。毛囊(hair follicle)由多种不同的皮膜细胞(epithelial cells)及毛乳头细胞(dermal papilla cells，DPCs)形成。毛乳头细胞为位于毛囊的基底部的间充质由来成纤维细胞(mesenchymally-derived fibroblasts)，对毛发生长起到重要的作用。尤其，据报道，米诺地尔(minoxidil)对毛乳头细胞具有增殖及抗细胞凋亡的效果。类似地，其他报告书中提出可通过毛乳头细胞的增殖促进毛发生。毛发分别具有不同的周期，经过生长期(anagen)、退化期(catagen)、休止期(telogen)生长并脱落。这种周期经过3～6年反复进行，正常情况下每日平均脱落50～100根毛发。通常，所谓的脱发症是指在这种周期中，生长期毛发的比率减少，而退化期或休止期毛发增多，从而导致所脱落的毛发的数量非正常地增加。
作为脱发的原因被议论中的有男性荷尔蒙作用过量论点、皮脂分泌过量论点、血液循环不良论点、因过氧化物、细菌等引起的皮质功能降低论点、遗传因素、老化、精神压力等。作为其原因之一的男性荷尔蒙的一种的睾丸素(testosteron)通过称之为5α-还原酶(5α-reductase)的酶激活为二氢睾丸酮(dihydrotestoserone；DHT)，上述二氢睾丸酮与特定受体相结合来诱导引起脱发的蛋白质，从而产生脱发。并且，因这种机制，还形成过多皮脂，并且引起粉刺、脂溢性皮肤炎等，因此皮质中显现出伴随着炎症的脱发。众所周知，脱发症(alopecia)是由疾病、营养不良、老化、荷尔蒙失衡等导致的。
像这样，尽管一直以来进行着有关脱发的诸多研究，但对于根本性的有关脱发的机制尚不清楚。并且，尽管一直以来还致力于脱发的治疗，但至今为止，美国食品药品管理局(FDA，Food and Drug Administration)(U.S.A)仅认可两种用于治疗脱发的药物(菲那雄胺(finasteride)及米诺地尔(minoxidil))。菲那雄胺作为5α-还原酶(5α-reductase)，一直以来用于促进男性的雄激素性脱发症(androgenetic alopecia)中的毛发生长。米诺地尔作为抗高血压剂(anti-hypertensive agent)，可通过ATP-敏感性K+-通道开放来促进毛发生长。然而，因无法预测的效果及副作用，药物的效果是有限性和暂时性的。因此，需要可预防脱发并促进毛发生长的疗效更好的新治疗药物。对于至今为止被公知为具有防止脱发且促进毛发生长效果的米诺地尔(minoxidil)或粘多糖生长素(trichosaccharide)等制剂而言，正在出现缺乏显著疗效及人体稳定性、引发皮肤刺激等副作用，因此当前实际情况为，急需开发一种确保稳定性及疗效的组合物。
为此，本发明人通过确认护脑素(HNG)的防止脱发及促进毛发生长的效果来完成了本发明。
发明内容
技术问题
本发明的目的在于，提供包含护脑素作为有效成分的用于防止脱发的药学组合物。
并且，本发明的目的在于，提供包含护脑素作为有效成分的用于促进毛发生长的化妆品组合物。
并且，本发明的目的在于，提供包含护脑素作为有效成分的用于防止脱发或促进毛发生长的保健食品。
解决问题的方案
本说明书中“脱发”意味着毛发从头皮脱落的现象或毛发变稀少或变细的状态，所谓“防止脱发”意味着预防且防止如上所述的脱发现象，所谓“促进毛发生长”意味着不仅促进新的毛发的生成，还使以往毛发健康生长。
通常，“毛发生长”在生长期中形成，通过从休止期向生长期的诱导及从生长期向退行期的延迟来进行促进。毛发周期可分为周知的生长期、退行期及休止期的3个主要步骤。在生长期中，与细胞的快速增殖一同，通过向皮肤内深处生长来完成毛囊毛发的形成。其次的现象为退行期，上述退行期为细胞分裂的中断脱颖而出的过渡期，在此过程中毛囊逐渐退化，并且毛发生长中断。在作为其次的现象的休止期中，退化毛囊包含具有稠密地充满的毛乳头(dermal papilla)细胞的胚芽(germ)。在休止期中新的生长期现象的开始通过从上述胚芽的快速细胞增殖、毛乳头的膨胀及基底膜要素的合成来进行诱导。
因此，需要生长期的促进或延长来防止毛发的损失，即，引起防止脱发或毛发的再生长，即，需要促进毛发生长，本发明的组合物包含使已存在的毛发不再脱落的效果、使已存在毛发改善成变粗等的效果及生长新的毛发的效果中的一种以上。毛乳头细胞(dermalpapilla cell)作为位于毛囊的基底的中胚层由来成纤维细胞，被认为通过与毛囊的毛基质细胞的相互作用，在毛发的生长中起到重要的作用(Jahoda CA，et al.，1984；OliverRF，et al.，1986)。因此可知，由于本发明的组合物激活毛乳头细胞，因而可以防止脱发并诱导毛发生长。
本发明提供包含护脑素作为有效成分的用于防止脱发的药学组合物。
上述护脑素是指由24个氨基酸形成的多肽(poly-peptide)，其在幸存于阿尔茨海默氏病(Alzheimer's disease)患者的大脑中的神经元中发现。具体地，本发明中所使用的护脑素(HNG)可以是原护脑素(HN)的第14个氨基酸碱基由丝氨酸(serine)被取代为甘氨酸(glycine)的护脑素(HNG)。已知相对于原护脑素(HN)的活性，上述本发明中所使用的护脑素(HNG)具有1000倍以上的优秀的预防阿尔茨海默氏病的效果(Hashimoto et al.，2001a，b，c)。
优选地，上述护脑素的浓度可以是0.01μM至10μM，具体是0.05μM至1μM，但不限于此。
在药学组合物中，相对于全部组合物的总重量，可以包含0.01重量百分比至70重量百分比的上述护脑素。
本发明的药学组合物可以为口服或非口服的各种剂型。在制剂化的情况下，利用通常使用的填充剂、增量剂、粘合剂、润湿剂、崩解剂、表面活性剂等的稀释剂或赋形剂来进行制备。用于口服给药的固体制剂中包含片剂、丸剂、散剂、颗粒剂、胶囊剂等，这种固体制剂在一种以上的化合物中混合至少一种的赋形剂，例如，淀粉、碳酸钙、蔗糖(sucrose)或乳糖(lactose)、明胶等来进行制备。并且，除了单纯的赋形剂之外，还使用硬脂酸镁、滑石等的润滑剂。悬浮液、内用液剂、乳剂、糖浆等属于作为用于口服给药的液体制剂，除了作为通常使用的单纯稀释剂的水、液体石蜡之外，可包含多种赋形剂，例如，润湿剂、甜味剂、芳香剂、防腐剂等。用于非口服给药的制剂中包含已灭菌的水溶液、非水溶剂、悬浮液、乳剂、冻干制剂、栓剂。
作为非水溶剂、悬浮溶剂可使用丙二醇(propylene glycol)、聚乙二醇、橄榄油等的植物油、油酸乙酯等的可进行注射的酯等。作为栓剂的基质可使用甘油明胶(witepsol)、聚乙二醇、吐温(tween)61、可可油脂、梓、甘油明胶等。
本发明的组合物的药学上的给药形态能够以上述组合物的药学上允许使用的盐的形态使用，并且能够以单独地或不仅与其他药学上的活性化合物相结合，还能够以适当的集合来使用。作为上述盐只要是药学上允许使用的，就不做特别限定，可使用例如，盐酸、硫酸、硝酸、磷酸、氢氟酸、氢溴酸、蚁酸、酒石酸、乳酸、柠檬酸、富马酸、马来酸、琥珀酸、甲磺酸、苯磺酸、甲苯磺酸、萘磺酸等。
本发明的组合物可根据所要达到的目的而进行非口服给药或口服给药，可在一日分1至数次来进行给药，使每1kg的体重以0.1mg至500mg的量进行给药。对于特定患者的给药量可根据患者的体重、年龄、性别、健康状态、膳食、给药时间、给药方法、排泄率、疾病的严重程度等来变化。
本发明的药学组合物分别根据常规的方法，包含粉剂、颗粒剂、片剂、胶囊剂、悬浮液、乳剂、糖浆、气雾剂等的口服型剂型、软膏、霜剂、凝胶、贴剂、喷雾剂、硬膏剂、洗剂等的外用剂、栓剂及灭菌注射用液等的适合于药剂学上的制剂的任意形态，都可进行剂型化来使用。
本发明的药学组合物可通过给大鼠、小鼠、家畜、人类等的哺乳动物进行非口服、口服等的多种路径来进行给药，给药的所有方法可预想，例如，可通过口服、直肠或静脉、肌肉、皮下、子宫内硬膜或脑血管内(intracerebroventricular)注射来进行给药。
另一方面，本发明的组合物因不存在太严重的毒性及副作用，因此当以预防为目的长时间使用时，也可放心使用。
并且，本发明提供包含护脑素作为有效成分的用于促进毛发生长的化妆品组合物。
优选地，上述护脑素的浓度可以是0.01μM至10μM，具体是0.05μM至1μM，但不限于此。
优选地，上述组合物为选自由生发水、润发乳、护发精华素、头发洗剂、头发营养水、洗发水、护发素、焗油膏、发乳、营养发乳、头发保湿霜、头发按摩霜、发蜡、头发喷雾剂、发膜、营养发膜、洗发皂、洗发奶、发油、毛发干燥剂、毛发防腐处理剂、染发剂、烫发剂、毛发脱色剂、发胶、毛发釉、美发剂、粘发剂、头发保湿剂、摩丝及定发剂组成的组中的剂型，但不限于此。
上述化妆品组合物可包含脂肪物质、有机溶剂、溶剂、增稠剂、胶凝剂、软化剂、抗氧化剂、悬浮剂、稳定化剂、发泡剂(foaming agent)、芳香剂、表面活性剂、水、离子型或非离子型乳化剂、填充剂、多价螯合剂、螯合剂、防腐剂、维生素、阻隔剂、润湿剂、必要的油、染料、颜料、亲水性或疏水性活化剂、脂质囊泡或化妆品中通常使用的任意其他成分等的化妆品学或皮肤科学领域中通常使用的助剂。上述助剂以化妆品学或皮肤科学领域中通常使用的量来导入。
根据上述的化妆品组合物可以为例如化妆品组合物，化妆品组合物的外形包含化妆品学或皮肤科学上允许使用的介质或基质。这作为适合局部应用的所用剂型，能够以例如，溶液、凝胶、固体、捏合无水生成物、在水相中分散油相所取得的乳胶、悬浮液、微乳剂、微囊剂、细颗粒剂或离子型(脂质体)及非离子型的囊泡分散剂的形态或霜剂、化妆水、乳液、散剂、软膏、喷雾剂或遮瑕棒的形态来提供。这些组合物可根据该领域的常规的方法来制备。本发明的组合物还能够以发泡(foam)的形态或还包含压缩的推进剂的气溶胶组合物的形态来使用。
本发明的化妆品组合物在剂型方面不受特别限制，可剂型化为例如，柔软化妆水、收敛化妆水、营养化妆水、营养霜、按摩霜、精华素、眼霜、眼部精华、洁面乳、洁面泡沫、洁面水、面膜、粉、润肤露、润肤乳、润肤油、美肌精华液等的化妆品。
如上所述的化妆品组合物能够以涂抹于皮肤的形态来利用，还可利用微型针等以向皮肤内部吸收的形态来适用。
并且，本发明的组合物可通过包含适合于涂敷毛发中的载体或载体混合物来制备成毛发组合物。载体包含与溶剂不同的载体或通常用于毛发保护组合物的赋形剂(vehicle)成分，在全部组合物的总重量中以约0.5％至99.5％，优选地，以约5.0％至95.0％，更优选地，以约10.0％至90.0％存在。作为载体，溶剂由共聚物来选择，上述共聚物无关于剂型化的毛发组合物与发胶、摩丝及发根营养液一同使用后残留于毛发或与洗发液、护发素等一同清洗而使用。优选地，在本发明中使用的适当的溶剂包含水、低级醇(乙醇、异丙醇等)、水醇类混合物、烃(异丁烷、己烷、葵烯等)、丙酮、卤代烃(氟利昂等)、烃酯(乙酸乙酯、邻苯二甲酸二丁酯等)、挥发性硅氧烷衍生物、硅氧烷(苯基五甲基二硅氧烷、甲氧基丙基甲基庚环四硅氧烷、氯丙基五甲基二硅氧烷、羟丙基五甲基二硅氧烷、八甲基环四、十甲基环戊硅氧烷等)及它们的混合物。
并且，本发明提供包含护脑素作为有效成分的用于防止脱发或促进毛发生长的保健食品。
优选地，上述护脑素的浓度可以是0.01μM至10μM，具体是0.05μM至1μM，但不限于此。
优选地，上述保健食品为粉末、颗粒、片剂、胶囊或饮料，但不限于此。
本发明的食品可以按原样添加上述护脑素或与其他食品或食品成分一同使用，并且可以根据常规方法适当地使用。
上述食品的种类不受特别限制。可添加上述护脑素的食品有例如肉类、香肠、面包、巧克力、糖果类、零食类、饼干类、比萨、拉面、其他面类、口香糖类、包括冰淇淋在内的乳制品、各种汤、饮用水、茶、饮料、酒精饮料及微生物复合剂等，并包括常规意义上的所有食品。
如同普通饮料，本发明的饮料组合物可以包含多种香味剂或天然碳水化合物作为附加成分。上述天然碳水化合物为诸如葡萄糖和果糖之类的单糖、诸如麦芽糖和蔗糖之类的二糖、诸如糊精和环糊精之类的多糖、以及木糖醇、山梨醇和赤藓糖等糖醇。作为甜味剂，可以使用诸如索马甜、甜叶菊提取物之类的天然香味剂或诸如糖精和阿斯巴甜之类的合成香味剂等。上述天然碳水化合物的比例通常为在每100ml的本发明的组合物中约0.01～0.04g，优选约0.02～0.03g。
除上述之外，本发明的食品可以包含多种营养素、维生素、电解质、风味剂、着色剂、果胶及其盐、藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、醇、碳酸饮料中所使用的碳酸化剂等。另外，可以包含用于制备天然果汁、果汁饮料、及蔬菜饮料的果肉。这种成分可以单独或混合使用。这种添加剂的比例不太重要，但通常在每100重量份的本发明的组合物中包含0.001～0.1重量份的范围内选择。
并且，本发明提供用于防止脱发或促进毛发生长的方法，包括将包含护脑素(Humanin)作为有效成分的组合物给药的步骤。
作为本发明的另一实例，提供包含护脑素(Humanin)作为有效成分的用于制备脱发防止或治疗剂、或毛发生长促进剂的组合物的用途。
由于本发明的上述方法及用途按原样利用包含上述护脑素的组合物，因而为了避免本说明书的过度复杂性，将省略对它们两者之间的相同内容的描述。
发明的效果
护脑素被认定为通过促进毛发生长中重要的毛乳头细胞的增殖来具有抑制及预防脱发且促进毛发生长的功效，因此可在药学、化妆品及美容等领域中以多种方式应用。
附图说明
图1为确认在不同浓度下护脑素的毛乳头细胞(DPCs)增殖促进效果的图。米诺地尔被用作阳性对照组，并且比较了利用护脑素(0.05μM、0.1μM、0.2μM及0.5μM)处理毛乳头细胞的状态。
图2为分离大鼠的生长期触须毛囊(vibrissa follicle)来确认不同浓度下的护脑素对毛囊的长度生长产生的影响的图。米诺地尔被用作阳性对照组，并且利用护脑素(0.05μM、0.1μM及0.2μM)处理触须毛囊来确认了毛囊的长度生长。
具体实施方式
以下，为了助于理解本发明，例举实施例来进行详细的说明。然而，下述实施例仅为用于例示本发明的内容，本发明的范畴并不由下述实施例而限定。本发明的实施例是为了给本发明所属技术领域中普通技术人员更加完整地说明本发明而提供。
实施例1：材料的准备及方法
1-1：准备护脑素
在本实验中使用了由PEPTIDE INSTITUTE，INC(Minoh，Osaka，日本)生产的护脑素(HNG)。该护脑素(HNG)是原护脑素(HN)的第14个氨基酸碱基由丝氨酸(serine)被取代为甘氨酸(glycine)的护脑素(HNG)。将护脑素(HNG)溶解在无菌三级蒸馏水中来制成0.1mM的护脑素(HNG)溶液后通过稀释来使用。
1-2：毛乳头细胞的培养
将从白鼠胡须中分离的永生化的毛乳头细胞(Rat vibrissa immortalizeddermal papilla cell：Filsell W，et al.，1994)利用包含100units/ml的青霉素(penicillin)-100μg/ml的链霉素(streptomycin)(Gibco Inc，纽约，美国)和10％的热灭活胎牛血清(heat-inactivated fetal bovine serum)(FBS；Gibco Inc，纽约，美国)的DMEM(Hyclone Inc，美国)培养基，在37℃的温度、5％的CO2恒温仪中进行了培养，并且每3天一次进行了继代培养。
1-3：统计分析方法
所有实验结果以平均±标准偏差或平均±标准误差求值并表示，通过学生t检验(student's t-test)进行统计学显著性检验，当p值(p-value)小于0.05时，判断为结果值具有显著性。统计处理使用了Sigma Stat统计软件(Sigma Stat software)(JandelScientific Software，美国)。
实施例2：通过四唑盐(MTT)分析确认毛乳头细胞的生长增殖功效
利用四唑盐比色法(MTT assay)测量了毛乳头细胞的增殖。将0.5×104cell/ml的毛乳头细胞混合于包含0.5％胎牛血清(FBS)的DMEM(Hyclone Inc，USA)并在96孔板(wellplate)中进行24小时培养之后，处理HNG，使其最终浓度达到50nM、100nM、200nM及500nM。作为阳性对照组的米诺地尔硫酸盐(minoxidil sulfate)以1μM的浓度进行了处理。在培养72小时之后，用2mg/ml的MTT溶液(Sigma，MO，USA)50μl进行处理，并进行了4小时的反应。在经过4小时之后离心分离，之后去除上清液，并添加200μl的DMSO使沉淀物溶解。利用VERSAmaxmicroplate reader(Molecular Devices，CA，USA)，在540nm下测量了上述溶解物的吸光度。利用不同浓度的护脑素(HNG)处理的毛乳头细胞中求出吸光度的平均值，并与对照组进行比较来确认了增殖程度。
毛乳头细胞作为位于毛囊的基底的中胚层由来成纤维细胞，其通过毛囊的毛基质细胞与位于凸起(bulge)的毛囊干细胞的相互作用，在毛发的生长中起到重要的作用。这种在毛发生长中起到重要作用的毛乳头细胞的增殖对于毛发生长的生长期(anagen)的诱导和维持方面非常重要。
当以50nM、100nM、200nM及500nM浓度处理护脑素(HNG)来确认毛乳头细胞增殖的结果，在经过72小时之后，相对于未处理试样的对照组，以50nM、100nM、200nM、500nM浓度处理护脑素(HNG)的毛乳头细胞的增殖分别呈现出98.51±9.87％、110.18±5.50％(P<0.01)、117.93±6.43％(P<0.001)、105.25±8.38％(图1)。当以200nM和100nM的浓度处理护脑素(HNG)时，确认到毛乳头细胞的增殖比对照组显著增加。
实施例3：确认护脑素诱导毛囊生长
将对出生3个星期的大鼠(rat)的左侧和右侧触须垫(mystacial pads)进行切割，放入E/P缓冲液(E/P buffer)(1：1vol./vol.solution of Earle's balanced saltssolution and phosphate-buffered saline supplemented with100U penicillin/mland 100μg streptomycin/ml)中。利用解剖显微镜观察切出的触须垫(mystacial pad)并使用解剖刀分离出触须毛囊(vibrissa follicle)。将分离的触须毛囊放入E培养基(William E medium)(William E medium supplemented with 2mM L-glutamine，10μg/mlinsulin，50nM hydrocortisone，100U/ml penicillin and 100μg/ml streptomycin)中，分别以50nM、100nM及200nM的浓度处理护脑素(HNG)并进行了培养。每3天更换新的E培养基(William E medium)，并且护脑素(HNG)也以50nM、100nM及200nM的浓度进行了处理。
每7天使用显微镜(Olympus，日本)对培养中的触须毛囊(vibrissa follicle)进行了拍摄，长度利用图像分析仪(image analyzer)(DP控制器；Olympus，日本)进行了测量。根据每个毛囊长度变化值来求出平均值，与对照组的毛囊长度变化值的平均值进行比较并检验了显著性(N＝7)。
当在第21天对护脑素(HNG)的处理组和对照组之间的毛囊的长度之差(％)进行比较的结果，在分别以50nM、100nM及200nM处理护脑素(HNG)的每组分别呈现出159.98±22.15％(P<0.05)、133.80±10.87％、124.94±28.70％的值(图2)。与对照组相比，以50nM处理护脑素(HNG)的组中毛囊长度显著增加。
制剂例1：制备片剂
根据片剂的常规制备方法，将上述多种成分以所提出的含量添加并均匀混合后搅拌，之后颗粒化。干燥后使用压片机制备出了每片含有1mg的护脑素作为有效成分的所需的片剂。
制剂例2：制备胶囊剂
根据胶囊剂的常规制备方法，将上述多种成分以所提出的含量添加并均匀混合后，以每个胶囊含有1mg护脑素的方式填充于适当大小的明胶胶囊中，从而制备出了所需的胶囊剂。
制剂例3：皮肤外用剂中的软膏
根据软膏的常规制备方法，通过以所提出的含量添加上述多种成分并均匀混合来制备出了软膏。
制剂例4：制备散剂
根据散剂的常规制备方法，通过混合上述多种成分并填充于气密布来制备出了散剂。
制剂例5：制备液剂
根据液剂的常规制备方法，通过混合上述多种成分来制备出了液剂。
制剂例6：制备生发水
根据生发水的常规制备方法，通过混合上述多种成分来制备生发水。
制剂例7：制备润发乳
根据润发乳的常规制备方法，通过混合上述多种成分来制备润发乳。
制剂例8：柔软化妆水(润肤液)
表1
根据上表1中所记载的组成来以常规方法制备出了柔软化妆水。
制剂例9：营养霜
表2
根据上表2中所记载的组成来以常规方法制备出了营养霜。
制剂例10：面膜
表3
根据上表3中所记载的组成来以常规方法制备出了面膜。
Claims (4)
1.护脑素在制备用于防止脱发的药学组合物中的用途，其中，所述护脑素在所述组合物中的浓度为0.1μM至0.2μM。
2.根据权利要求1所述的用途，其特征在于，上述用于防止脱发的药学组合物为选自由片剂、胶囊剂、注射剂、霜剂、凝胶剂、贴剂、喷雾剂、软膏剂、硬膏剂、洗剂、擦剂、糊剂及泥敷剂组成的组中的剂型。
3.护脑素在制备用于防止脱发或促进毛发生长的化妆品组合物中的用途，其中，所述护脑素在所述组合物中的浓度为0.1μM至0.2μM。
4.根据权利要求3所述的用途，其特征在于，上述用于防止脱发或促进毛发生长的化妆品组合物为选自由生发水、头发洗剂、护发素、发乳、发膜、洗发皂、毛发防腐处理剂、美发剂及定发剂组成的组中的剂型。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0121112 | 2017-09-20 | ||
| KR1020170121112A KR102079977B1 (ko) | 2017-09-20 | 2017-09-20 | 휴매닌(Humanin)을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 |
| PCT/KR2018/004549 WO2019059485A1 (ko) | 2017-09-20 | 2018-04-19 | 휴매닌을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111107867A CN111107867A (zh) | 2020-05-05 |
| CN111107867B true CN111107867B (zh) | 2023-07-04 |
Family
ID=65809682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880061002.8A Active CN111107867B (zh) | 2017-09-20 | 2018-04-19 | 包含护脑素的防止脱发或毛发生长促进用组合物 |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102079977B1 (zh) |
| CN (1) | CN111107867B (zh) |
| WO (1) | WO2019059485A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230033705A1 (en) * | 2021-07-26 | 2023-02-02 | Zhejiang University | Method for carbon dioxide capture and concentration by partitioned multistage circulation based on mass transfer-reaction regulation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003111594A (ja) * | 2001-06-15 | 2003-04-15 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびその用途 |
| CN1777812A (zh) * | 2003-03-17 | 2006-05-24 | 艾尼纳制药公司 | 人类g蛋白偶联受体和用于治疗细胞死亡相关病症的其调节物 |
| US20170216399A1 (en) * | 2014-09-12 | 2017-08-03 | Los Angeles Biomedical Research Institute At Harbo-Ucla Medical Center | Compositions, methods and uses for protecting white blood cells from suppression or death |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006213632A (ja) * | 2005-02-03 | 2006-08-17 | Takeda Chem Ind Ltd | 癌治療の副作用予防・軽減剤 |
| KR101885591B1 (ko) * | 2015-11-25 | 2018-08-06 | 주식회사 바이오에프디엔씨 | 휴매닌 또는 이의 유사체를 유효성분으로 함유하는 창상 치료용 약학적 조성물 |
-
2017
- 2017-09-20 KR KR1020170121112A patent/KR102079977B1/ko active IP Right Grant
-
2018
- 2018-04-19 CN CN201880061002.8A patent/CN111107867B/zh active Active
- 2018-04-19 WO PCT/KR2018/004549 patent/WO2019059485A1/ko active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003111594A (ja) * | 2001-06-15 | 2003-04-15 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびその用途 |
| CN1777812A (zh) * | 2003-03-17 | 2006-05-24 | 艾尼纳制药公司 | 人类g蛋白偶联受体和用于治疗细胞死亡相关病症的其调节物 |
| US20170216399A1 (en) * | 2014-09-12 | 2017-08-03 | Los Angeles Biomedical Research Institute At Harbo-Ucla Medical Center | Compositions, methods and uses for protecting white blood cells from suppression or death |
Non-Patent Citations (4)
| Title |
|---|
| Detailed Characterization of Neuroprotection by a Rescue Factor Humanin against Various Alzheimer’s Disease-Relevant Insults;Yuichi Hashimoto et al.;《The Journal of Neuroscience》;20011201;摘要 * |
| Humanin is a novel neuroprotective agent against stroke;XU, X. S. et al.;《Stroke》;20061231;第2613-2619页 * |
| Humanin rescues human cerebrovascular smooth muscle cells from Aβ-induced toxicity;JUNG, S. S. et al.;《Journal of Neurochemistry》;20031231;第266-272页 * |
| The neurosurvival factor humanin inhibits beta cell apoptosis via Stat 3 activation and delays and ameliorates diabetes in NOD mice;HOANG,P. T. et al.;《Metabolism:Clinical and Experimental》;20101231;第343-349页 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230033705A1 (en) * | 2021-07-26 | 2023-02-02 | Zhejiang University | Method for carbon dioxide capture and concentration by partitioned multistage circulation based on mass transfer-reaction regulation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190033104A (ko) | 2019-03-29 |
| KR102079977B1 (ko) | 2020-04-08 |
| WO2019059485A1 (ko) | 2019-03-28 |
| CN111107867A (zh) | 2020-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120107427A1 (en) | Composition for promoting adipocyte differentiation containing an extract of rehmannia glutinosa, licorice, coicis semen, hordei fructus, chaenomelis fructus, acanthopanacis cortex or puerariae radix | |
| KR101772574B1 (ko) | 모낭 세포의 재생과 성장을 촉진하는 성장인자, 고안정성 섬유아세포 성장인자 변이체 및 노긴 펩타이드를 함유한 헤어케어 화장품 조성물 | |
| CN112041329A (zh) | 用于预防脱发或促进毛发生长的组合物 | |
| KR102535575B1 (ko) | 고안정성 섬유아세포 성장인자-9 변이체를 유효성분으로 포함하는 헤어케어 화장품 조성물 | |
| RU2711298C2 (ru) | Композиция для предотвращения или лечения выпадения волос, содержащая белок хемокинового лиганда 1, содержащего с-х-с мотив (cxcli) | |
| CN111107867B (zh) | 包含护脑素的防止脱发或毛发生长促进用组合物 | |
| CN112220794B (zh) | 柠檬苦素的防脱发和生发用途 | |
| KR101541470B1 (ko) | 진세노사이드 ｆ2를 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| JP6860558B2 (ja) | ソヤサポニンを含有する発毛および／または育毛促進用組成物 | |
| KR102591604B1 (ko) | 코나루스 세미데칸드러스 잭. 추출물을 포함하는 탈모 예방 또는 치료용 약학적 조성물 | |
| WO2023022540A1 (ko) | 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
| KR101701217B1 (ko) | 밤송이로부터 추출된 물질을 함유하는 탈모 예방 또는 치료용 약학 조성물 | |
| KR101529380B1 (ko) | 적하수오에서 분리한 화합물을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 | |
| CN105392492B (zh) | 含有麦皮提取物作为有效成分的防脱发或促进毛发生长的组合物 | |
| KR101609436B1 (ko) | 갈고리가시우무 추출물을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 | |
| CN111107861B (zh) | 昌化鹅耳枥叶的乙醇提取物在制备用于防止脱发的药学组合物中的用途 | |
| CN106572983B (zh) | 包含3-溴-4，5-二羟基苯甲醛化合物作为有效成分防止脱发或毛发生长促进用组合物 | |
| KR101556498B1 (ko) | 아스트라갈로시드 ｉｖ를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
| KR101609437B1 (ko) | 갈고리참곱슬이 추출물을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 | |
| KR20120075766A (ko) | 탈모방지 또는 발모촉진용 조성물 | |
| KR101777478B1 (ko) | 클라이토사이빈 에이(Clitocybin A)를 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물 | |
| RU2794988C1 (ru) | Композиция для предупреждения выпадения волос или стимуляции роста волос | |
| KR102405779B1 (ko) | 쐐기풀을 포함하는 기능성 조성물 및 이의 제조방법 | |
| KR102011826B1 (ko) | 인터루킨 13을 포함하는 피부 외용제 조성물 | |
| KR102406692B1 (ko) | 콩발아배아 추출물을 유효성분으로 포함하는 발모 촉진용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |